Big pharma's Pfizer (PFE 0.38%) has dominated the news in May after reports exploded over the company's interest in buying rival AstraZeneca (AZN -0.87%). It's a big need: Pfizer's struggled with sales growth lately as the patent cliff's effects on former top sellers such as cholesterol-fighting drug Lipitor have taken a hammer to the company's revenue. It certainly hasn't helped Pfizer's stock, which has disappointed investors in losing more than 8% over the past three months.
But can long-term shareholders find the silver lining in this stock's recent downturn? The AstraZeneca interest has sparked conflicting opinions from seemingly every source, but Pfizer's intent on gearing up its pipeline through a big buy -- or a surprise sale to focus on its growth businesses -- could be just the spark investors are looking for.
What should you be watching most for this company in the coming months? Find out in the video below, as Motley Fool contributor Dan Carroll takes you through the three biggest trends to watch for Pfizer -- and whether or not this stock's ready to make a comeback through the rest of 2014.
